News | Pulmonary Embolism | February 22, 2023

RapidAI Receives FDA 510(k) Clearance for Pulmonary Embolism Product

Integrated with the Rapid PE solution, Rapid RV/LV further accelerates time to triage and diagnose pulmonary embolism patients with right heart strain

Integrated with the Rapid PE solution, Rapid RV/LV further accelerates time to triage and diagnose pulmonary embolism patients with right heart strain

February 22, 2023 — RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid RV/LV, the newest addition to the Rapid PE solution. The tool empowers physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity. Automating this process will enable care teams to more quickly prioritize patients and accelerate decision making. 

Rapid RV/LV uses AI to analyze Computerized Tomography Pulmonary Angiograms (CTPAs) and automatically calculate the RV/LV ratio within minutes of the scan, enabling physicians to more quickly conduct risk stratification for patients with right heart strain. Combined with the results from the Rapid PE triage and notification product, which notifies clinicians of suspected PE, and the workflow and communication tools of the Rapid Workflow mobile and web apps, PE care teams now have the information they need at their fingertips to make faster care decisions and to communicate with and activate the team for truly coordinated care. 

“Rapid PE streamlines the care pathway from the moment a suspected PE patient is scanned, to diagnosis and through treatment – reducing the complexities that come with managing PE, helping teams triage patients faster, and reducing overall time to treatment,” said Karim Karti, CEO of RapidAI. “The FDA clearance of Rapid RV/LV further enhances our PE solution by providing physicians with an immediate view into patients suffering from RV strain, which is critical to getting the right patients to the right care as fast as possible. This is yet another step toward delivering AI-based solutions that help physicians further enhance patient care and impact patient outcomes to ultimately improve quality of life – something we are very proud to be part of.” 

As a component of the Rapid PE solution, the key benefits of Rapid RV/LV include: 

  • Quickly identifies patients with possible right heart strain 
  • Reduces time to diagnosis 
  • Reduces variability and standardizes RV/LV measurement 

“Elevated risk PE is a treatable disease, but it is underdiagnosed. Rapid RV/LV will be key in identifying PE patients with right heart strain,” said Dr. Peter Monteleone, Interventional Cardiologist at Ascension Texas Cardiovascular. “The ability to access the RV/LV ratio along with CTPA images will allow clinicians to quickly identify patients who would benefit from further treatment, improving patient outcomes and saving lives. This will have a profound impact on our PE program here at Ascension.” 

For more information: https://www.rapidai.com/pe 


Related Content

News | Pulmonary Embolism

March 10, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home March 10, 2023
Home
News | Pulmonary Embolism

November 17, 2022 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced the ...

Home November 17, 2022
Home
News | Pulmonary Embolism
February 16, 2022 – Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a ...
Home February 16, 2022
Home
News | Pulmonary Embolism

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the ...

Home February 14, 2022
Home
News | Pulmonary Embolism

August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative ...

Home August 09, 2021
Home
News | Pulmonary Embolism

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
News | Pulmonary Embolism

October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than ...

Home October 18, 2019
Home
News | Pulmonary Embolism

March 4, 2019 — Artificial intelligence (AI) radiology solution provider Aidoc announced the commercial release of its ...

Home March 04, 2019
Home
News | Pulmonary Embolism

October 23, 2018 — Daniel J. Schimmel, Jr., M.D., MS, a cardiologist at Northwestern Memorial Hospital, recently ...

Home October 23, 2018
Home
News | Pulmonary Embolism

June 29, 2018 — Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with ...

Home June 29, 2018
Home
Subscribe Now